Go Deep
Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,534 | -1.4 | 2.97 | 1.52 | 94.43 |
| Oct 2026 | 18,606 | -1.3 | 2.92 | 1.52 | 92.82 |
| Oct 2026 | 16,552 | -1.4 | 3.10 | 1.52 | 98.61 |
| Oct 2026 | 16,510 | -1.4 | 3.13 | 1.52 | 99.56 |
| Oct 2026 | 16,594 | -1.4 | 3.07 | 1.52 | 97.42 |
| Oct 2026 | 16,679 | -1.4 | 3.01 | 1.52 | 95.33 |
Werewolf Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 21,000,000.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 3,670,000.0 | -13,532,000.0 | -8,381,000.0 | -16,370,000.0 |
| EPS | 0.1 | -0.3 | -0.2 | -0.4 |
Werewolf Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 1,885,000.0 | 19,943,000.0 | 16,401,000.0 | — |
| Net Profit | -60,822,000.0 | -70,515,000.0 | -37,368,000.0 | -53,810,000.0 | — |
| EPS | -1.3 | -1.6 | -1.1 | -1.9 | — |
Werewolf Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 69,396,000.0 | 126,929,000.0 | 174,833,000.0 | 160,245,000.0 | — |
| Total Liabilities | 44,591,000.0 | 53,539,000.0 | 63,459,000.0 | 37,908,000.0 | — |
| Total Equity | 24,805,000.0 | 73,390,000.0 | 111,374,000.0 | 122,337,000.0 | — |
Owes vs Owns
Werewolf Therapeutics, Inc. owed $0.33 for every $1 it owned in Jun 2026, up from $0.24 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.33× | 0.64× | 0.42× | 0.36× | 0.24× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Werewolf Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 82.2%Fixed assets (tangible) 14.3%Other assets 3.5%
How it's funded — Dec 2025
Short-term debt 40.7%Long-term debt 11.1%Payables 1.1%Other liabilities 11.4%Shareholders' equity 35.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 57.0 | 111.0 | 134.3 | 129.3 |
| Receivables | 0.0 | 0.0 | 1.4 | 6.9 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 9.9 | 12.3 | 14.8 | 17.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.4 | 3.6 | 24.3 | 6.6 |
| Liabilities & equity | ||||
| Short-term debt | 28.2 | 1.6 | 6.7 | 2.1 |
| Long-term debt | 7.7 | 26.1 | 32.7 | 12.6 |
| Payables | 0.8 | 3.0 | 1.3 | 1.2 |
| Other liabilities | 7.9 | 22.9 | 22.8 | 22.0 |
| Shareholders' equity | 24.8 | 73.4 | 111.4 | 122.3 |
| Net tangible assets | 24.8 | 73.4 | 111.4 | 122.3 |
Werewolf Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -60,292,000.0 | -56,188,000.0 | -32,612,000.0 | -40,596,000.0 | — |
| Investing Activities | 0.0 | -254,000.0 | -769,000.0 | -3,611,000.0 | — |
| Financing Activities | 6,028,000.0 | 13,080,000.0 | 58,429,000.0 | 15,906,000.0 | — |